By Andrew Pollack Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. Boehringer Ingelheim said ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

The Catalysis group at Boehringer Ingelheim works with various internal and external partners to develop synthetic technologies that speed up the delivery of lifesaving drugs to patients. The webinar ...

Boehringer Ingelheim was given the opportunity to ... hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Ann Am Thorac Soc.

Financial disclosures include relationships with Boehringer Ingelheim and United Therapeutics through consultancies and lecture fees. Anthony J. Esposito, MD, and Evans R. Fernández Peréz ...

11 This reflects the importance of such meetings that urge the healthcare community to stand united in the fight against heart failure and its interconnected conditions.” As a leading ...

IntegriChain, the leading provider of pharma revenue optimization technology and insights for the pharmaceutical industry, announced the winners of its annual customer awards at the Access Insights ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...